Laurence E. Krieger

2.8k total citations · 1 hit paper
26 papers, 518 citations indexed

About

Laurence E. Krieger is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Laurence E. Krieger has authored 26 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 13 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Laurence E. Krieger's work include Bladder and Urothelial Cancer Treatments (18 papers), Cancer Research and Treatments (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Laurence E. Krieger is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Cancer Research and Treatments (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Laurence E. Krieger collaborates with scholars based in Australia, United States and Canada. Laurence E. Krieger's co-authors include Edward Uchio, Ronald de Wit, Petros Grivas, Eric A. Singer, Ashish M. Kamat, Dean F. Bajorin, Ho Kyung Seo, Arjun Vasant Balar, Girish S. Kulkarni and Kijoeng Nam and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Laurence E. Krieger

22 papers receiving 512 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurence E. Krieger Australia	8	447	217	109	92	84	26	518
Ekta Kapadia United States	8	511 1.1×	224 1.0×	120 1.1×	83 0.9×	102 1.2×	24	575
Truls Gårdmark Sweden	12	380 0.9×	185 0.9×	78 0.7×	69 0.8×	105 1.3×	48	522
José Portillo Spain	6	590 1.3×	144 0.7×	72 0.7×	69 0.8×	186 2.2×	18	643
Christien Caris Netherlands	9	269 0.6×	136 0.6×	51 0.5×	114 1.2×	111 1.3×	21	439
Armine K. Smith United States	9	424 0.9×	90 0.4×	73 0.7×	128 1.4×	171 2.0×	27	541
Hugh Mostafid United Kingdom	8	274 0.6×	69 0.3×	79 0.7×	63 0.7×	85 1.0×	26	345
Ashish M. Kamat United States	10	546 1.2×	109 0.5×	89 0.8×	99 1.1×	175 2.1×	15	576
Kenta Ohnishi Japan	10	183 0.4×	145 0.7×	104 1.0×	79 0.9×	34 0.4×	16	372
Manuel Sierra Montesinos Spain	6	794 1.8×	169 0.8×	113 1.0×	97 1.1×	251 3.0×	13	839
Jesús Rodríguez-Molina Spain	7	797 1.8×	210 1.0×	123 1.1×	123 1.3×	251 3.0×	7	873

Countries citing papers authored by Laurence E. Krieger

Since Specialization

Citations

This map shows the geographic impact of Laurence E. Krieger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence E. Krieger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence E. Krieger more than expected).

Fields of papers citing papers by Laurence E. Krieger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence E. Krieger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence E. Krieger. The network helps show where Laurence E. Krieger may publish in the future.

Co-authorship network of co-authors of Laurence E. Krieger

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence E. Krieger. A scholar is included among the top collaborators of Laurence E. Krieger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence E. Krieger. Laurence E. Krieger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marx, Gavin, Simon Chowdhury, Laurence E. Krieger, et al.. (2024). A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 20(4). 435–443.

Gedye, Craig, Carole A. Harris, Martin R. Stockler, et al.. (2023). 1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Annals of Oncology. 34. S1014–S1014.

Bryce, Alan H., Josep M. Piulats, M. Neil Reaume, et al.. (2023). Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.. Journal of Clinical Oncology. 41(6_suppl). 18–18. 10 indexed citations

Powles, Thomas, Evan Y. Yu, Gopa Iyer, et al.. (2023). Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001).. Journal of Clinical Oncology. 41(6_suppl). TPS594–TPS594. 12 indexed citations

Galsky, Matthew D., Peter H. O’Donnell, Earle F. Burgess, et al.. (2022). 663 Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress). Regular and Young Investigator Award Abstracts. A693–A693. 2 indexed citations

Krieger, Laurence E., et al.. (2021). Superficial radiotherapy and volumetric modulated Arc therapy for skin cancers within hamartomatous skin in patient with PTEN mutation: A case report. 8(1). 26–30. 1 indexed citations

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2021). UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.. Journal of Clinical Oncology. 39(6_suppl). 325–325. 2 indexed citations

Liow, Elizabeth, Dickon Hayne, Martin R. Stockler, et al.. (2020). Adding mitomycin to Bacillus Calmette-Guérin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301).. Journal of Clinical Oncology. 38(6_suppl). TPS602–TPS602. 1 indexed citations

10.

Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2020). Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.. Journal of Clinical Oncology. 38(15_suppl). 5041–5041. 23 indexed citations

11.

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2020). UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).. Journal of Clinical Oncology. 38(6_suppl). TPS768–TPS768. 1 indexed citations

12.

Sternberg, Cora N., Yohann Loriot, Rosa Tambaro, et al.. (2020). Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma.. Journal of Clinical Oncology. 38(6_suppl). 488–488. 2 indexed citations

13.

Boormans, Joost L., Ronald de Wit, Edward Uchio, et al.. (2020). Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). European Urology Open Science. 19. e1173–e1174. 2 indexed citations

14.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.. Journal of Clinical Oncology. 37(15_suppl). 4530–4530. 4 indexed citations

15.

Wit, Ronald de, Arjun Vasant Balar, Ashish M. Kamat, et al.. (2019). MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN. The Journal of Urology. 201(Supplement 4). 4 indexed citations

16.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). Annals of Oncology. 30. v364–v365. 3 indexed citations

17.

Boormans, Joost L., Arjun Vasant Balar, Ronald de Wit, et al.. (2019). Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study. European Urology Supplements. 18(1). e758–e759. 1 indexed citations

18.

Balar, Arjun Vasant, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).. Journal of Clinical Oncology. 37(7_suppl). 350–350. 80 indexed citations

19.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2018). Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial. Annals of Oncology. 29. viii304–viii304. 9 indexed citations

20.

Gunaratne, Dakshika A., et al.. (2015). Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature. Clinical Genitourinary Cancer. 14(1). e103–e105. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact